Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Corvus Pharmaceuticals (CRVS) Assets Average (2016 - 2026)

Corvus Pharmaceuticals' Assets Average history spans 11 years, with the latest figure at $162.2 million for Q1 2026.

  • Quarterly Assets Average rose 152.69% to $162.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $162.2 million through Mar 2026, up 152.69% year-over-year, with the annual reading at $70.0 million for FY2025, 22.34% up from the prior year.
  • Assets Average came in at $162.2 million for Q1 2026, up from $75.8 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $162.2 million in Q1 2026 to a low of $42.8 million in Q1 2024.
  • The 5-year median for Assets Average is $64.2 million (2025), against an average of $74.7 million.
  • Year-over-year, Assets Average tumbled 40.03% in 2023 and then surged 152.69% in 2026.
  • Corvus Pharmaceuticals' Assets Average stood at $74.3 million in 2022, then crashed by 34.39% to $48.7 million in 2023, then skyrocketed by 31.0% to $63.9 million in 2024, then grew by 18.69% to $75.8 million in 2025, then skyrocketed by 113.94% to $162.2 million in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Assets Average are $162.2 million (Q1 2026), $75.8 million (Q4 2025), and $85.0 million (Q3 2025).